Draft:Allurion Technologies
| Company type | Public (Société Anonyme) |
|---|---|
| NYSE:ALUR | |
| Industry | Medical Technology |
| Founded | 2009 |
| Headquarters | Natick, Massachusetts |
Key people | Dr Shantanu Gaur, CEO and Founder |
| Products | Allurion Gastric Balloon, VCS |
Number of employees | 120 |
| Website | http://www.allurion.com |
Allurion Technologies is a global medical device company focused on weight loss. The company researches, develops and markets medical and digital tools to help people lose weight.
The company makes The Allurion Gastric Balloon, is a Non-Endoscopic Intragastric Balloon. The Allurion Gastric Balloon, except under exceptional circumstances, does not require endoscopy or surgery for placement or removal.[1]
Allurion went public in August 2023 and trades on the NYSE.[2]
The Allurion Gastric Balloon System
[edit]Procedureless, or non-endoscopic, intragastric balloons offer a promising alternative to historic endoscopic balloons. Non-endoscopic balloons are also a less invasive alternative to weight-loss surgery.[1]
In 2015, Allurion's gastric balloon became the world's first non-endoscopic swallowable gastric balloon when it gained approval in Europe.[3][4] Except under exceptional circumstances, it does not require endoscopy or surgery for placement or removal.[1] The non-endoscopic gastric balloon capsule is swallowed for placement and once in the stomach is filled with saline liquid. After approximately 4 months, the non-endoscopic gastric balloon then self-deflates and passes naturally at the end of placement. A recent meta analysis of 6 studies found the balloon was a safe device offering effective weight loss. Total pooled weight loss at the completion of treatment (4–6 months) was 12.8% and at 12 months was 10.9%.[4]
Timeline
[edit]| History | |
|---|---|
| 2009 | Founding of Allurion Technologies by Shantanu Gaur and Samuel Levy while they were studying at Harvard Medical School. |
| 2015 | Won CE Mark approval in the European Union for its gastric balloon [5] |
| 2021 | Allurion Launches Virtual Care Suite, an upgraded digital experience for doctors to track their patients success[6] |
| 2022 | Allurion launches digital advancement the Allurion Iris™ Artificial Intelligence Platform and introduces Success Predictor, a machine-learning algorithm that predicts outcomes as early as 20 days from the start of the Allurion Program |
| 2023 | Allurion becomes a public company, trading on the NYSE |
References
[edit]- ^ a b c Ienca, R.; Al Jarallah, Mohammed; Caballero, Adelardo; et al. (September 2020). "The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients". Obesity Surgery. 30 (9): 3354–3362. doi:10.1007/s11695-020-04539-8.
- ^ Finance, Yahoo. "Allurion Debuts as a Publicly Traded Company on the NYSE". Yahoo Finance. Yahoo. Retrieved 28 May 2024.
- ^ “Allurion Technologies’ Elipse® Program Demonstrates Significant Weight Loss in Findings Presented at 24th World IFSO Congress”. Business Wire. Retrieved 2021-02-16.
- ^ a b Vantanasiri, Kornpong; Matar, Reem; Beran, Azizullah; et al. (September 2020). "The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis". Obesity Surgery. 30 (9): 3341–3346. doi:10.1007/s11695-020-04522-3.
- ^ Device, Mass. "Allurion wins CE Mark for weight loss balloon". Mass Device. Mass Device. Retrieved 28 May 2024.
- ^ "Allurion Technologies Launches Virtual Care Suite to Transform the Consumer and Provider Experience". Business Wire. Jan 26, 2021. Retrieved 21 May 2024.